Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Dermatologic 2

Conditions

Melanoma 5Crohn Disease 4Colitis, Ulcerative 4Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Inflammatory Bowel Diseases 3Colitis 3Arthritis, Rheumatoid 3Urogenital Neoplasms 2Inflammation 2Hematologic Neoplasms 2Graft vs Host Disease 2Fatigue 2Depressive Disorder, Major 2Depression 2Cachexia 2Anorexia 2Vasculitis 1Takayasu Arteritis 1Syndrome 1Stroke 1Stevens-Johnson Syndrome 1Skin Neoplasms 1Recurrence 1Rare Diseases 1Pemphigoid, Benign Mucous Membrane 1Pancreatic Neoplasms 1Lymphoma 1Kidney Transplantation 1Hypertension 1

Interventions

Infliximab 3Fecal Microbiota Transplantation 3vedolizumab 2Prednisone 2Methylprednisolone 2LDP-02 2Immunoglobulin G 2Disulfides 2CT-P13 2tocilizumab 1prednylidene 1fish oil triglycerides 1deltacortene 1Standard of Care 1Practice Guidelines as Topic 1Methylprednisolone Hemisuccinate 1Loperamide 1Injections 1Endoscopy 1Colonoscopy 1Cell- and Tissue-Based Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Colitis × Infliximab × Clear all
NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
800 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡